Lupin's share price spiked nearly 5 per cent on Wednesday ahead of the company's Q4FY26 results that are set to be announced on May 7. The company is likely to report a strong operational performance in Q4, with revenues projected to grow nearly 22 per cent year-on-year to Rs 6,909.3 crore and EBITDA rising sharply by nearly 45.7 per cent, aided by robust traction in the US market and steady domestic growth.

Moreover, profit after tax is likely to surge 55.6 per cent.

LUPIN Q4 Preview

Consensus expectations: (Cons YoY)

• Revenue seen at Rs 6,909.3 vs Rs 5,667.1 cr, Up 21.9 per cent YoY
• EBITDA seen at Rs 1,882.2 vs Rs 1,292.1 cr, Up 45.7 per cent YoY
• EBITDA Margin seen at 27.2 per cent vs 22.8 per cent, Up 444.2bps YoY
• PAT seen at Rs 1,202 vs Rs 772.5 cr, Up 55.6 per cent YoY

Key Expectations From Lupin Q4FY26

• Strong quarter expected, Revenue growth 15-20 per cent YoY
• India business growth 7-10 per cent YoY
• US biz to grow in double digits supported by launches
• Margins expected lower QoQ - higher R&D, SG&A (lack of PLI benefits) and Mirabegron licensing fee

Key Monitorables From Lupin Q4FY26

• Contributions from new launches: Mirabegron, Tolvaptan and gXarelto.
• VISU pharma integration
• Pricing pressure in Albuterol.
• Licensing and supply agreement with Zydus for Semaglutide in India (Semaglutide brands: Semanext, Livarise)

FY26 Guidance given

• ETR to be about 21 per cent to 22 per cent
• R&D expense: 7.5 per cent to 8.5 per cent of sales
• EBITDA margin: 27 per cent to 28 per cent

Lupin Share Price

Lupin's share price surged nearly 5 per cent to Rs 2,458 apiece on Wednesday ahead of the company's Q4FY26 results. Lupin has delivered strong short-term momentum, with the stock gaining 6.21 per cent over the past week, significantly outperforming the NIFTY Midcap 50, which rose 1.29 per cent in the same period. Over a one-month timeframe, the stock is up 7.68 per cent, though it has slightly lagged the broader midcap index, which advanced 11.23 per cent

On a year-to-date (YTD) basis, Lupin continues to show resilience, rising 16.75 per cent compared to a marginal 0.54 per cent decline in the NIFTY Midcap 50, indicating strong relative outperformance. The one-year return also remains healthy at 19.81 per cent, ahead of the benchmark's 14.08 per cent, reflecting steady investor confidence in the stock.

Over the longer term, Lupin has delivered substantial gains, surging 248.55 per cent over three years, surpassing the 90.88 per cent rise in the midcap index. However, its five-year return of 104.87 per cent trails the 152.52 per cent gain in the NIFTY Midcap 50.

(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money related decisions.)